HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
← catalyst calendarNCT06824155 · readout ≤ 499 d
Sponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →.
Phase
Early Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
5
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-12 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HER2 Gene Mutation
- Advanced Solid Tumors
Intervention
- Drug: 177Lu-RAD202
Primary outcomes
what the primary-completion date above is the date OFTime Activity Curves (TACs)
measured 72 hours
Radiation dosimetry of Lu177-RAD202im
measured 72 hours
Safety and tolerability of a single dose of 177Lu-RAD202tr
measured 6 weeks
Recommended dose(s) of 177Lu-RAD202tr for future exploration
measured 6 weeks
Pharmacokinetics of 177Lu-RAD202im
measured 72 hours
Biokinetics of 177Lu-RAD202im
measured 72 hours
Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed